✦ LIBER ✦

Intensity fluctuations due to a deeply modulated phase screen—II. Results

✍ Scribed by C. Macaskill; B.J. Uscinski

Book ID: 117135316
Publisher: Elsevier Science
Year: 1983
Tongue: English
Weight: 505 KB
Volume: 45
Category: Article
ISSN: 0021-9169
DOI: 10.1016/s0021-9169(83)80077-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intensity fluctuations due to a deeply m

Intensity fluctuations due to a deeply modulated phase screen—I. Theory

✍ B.J. Uscinski; C. Macaskill 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 615 KB

Urethral Sparing Intensity Modulated Rad

Urethral Sparing Intensity Modulated Radiation Therapy (US-IMRT) Is Not Shown To Improve Urinary Quality of Life (QOL) in Low Risk Prostate Cancer (PCa): Results of a Randomized Phase II Trial

✍ J.M. Vainshtein; E. Abu-Isa; K. Olson; M.E. Ray; H.M. Sandler; D. Normolle; C. P 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

A Phase II Study of Intensity Modulated

A Phase II Study of Intensity Modulated Radiation Therapy to the Pelvis for Postoperative Patients With Endometrial Carcinoma: Radiation Therapy Oncology Group Trial 0418

✍ Anuja Jhingran; Kathryn Winter; Lorraine Portelance; Brigitte Miller; Mohammad S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 496 KB

A Phase II Multi-institutional Study of

A Phase II Multi-institutional Study of Postoperative Pelvic Intensity Modulated Radiation Therapy (IMRT) with Weekly Cisplatin in Patients with Cervical Carcinoma: Two Year Efficacy Results of the RTOG 0418

✍ L. Portelance; J. Moughan; A. Jhingran; B.E. Miller; M.R. Salehpour; D. D'Souza; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Phase II Trial of Hypofractionated Inten

Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme

✍ K. Reddy; D. Damek; L. Gaspar; D. Ney; B. Kavanagh; A. Waziri; K. Lillehei; K. S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 40 KB

The trifunctional antibody catumaxomab f

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

✍ Markus M. Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O. Kol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 559 KB

## Abstract Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule x anti‐CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascite